Cargando…

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing

The introduction of effective systemic therapies has significantly changed the treatment of stage III and IV melanoma. Both immune checkpoint inhibitors and targeted therapies have improved recurrence-free survival in the adjuvant setting. Recent interest has sparked for neoadjuvant systemic therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Akkooi, Alexander C. J., Zijlker, Lisanne P., Wouters, Michel W. J. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148869/ https://www.ncbi.nlm.nih.gov/pubmed/35397089 http://dx.doi.org/10.1007/s40259-022-00525-x

Ejemplares similares

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
por: Rohaan, Maartje W., et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma
por: Ferraresi, Virginia, et al.
Publicado: (2021)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
por: Sarver, Melissa, et al.
Publicado: (2021)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis
por: Li, Xin, et al.
Publicado: (2017)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy
por: Wu, Qinghua, et al.
Publicado: (2022)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
por: Thomas, Rachel, et al.
Publicado: (2021)

Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy
por: Pradeep, Jnaneshwari, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitors and targeted therapies in resected melanoma: a systematic review and network meta-analysis
por: Sheng, Feng, et al.
Publicado: (2023)

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
por: Schouwenburg, Maartje G., et al.
Publicado: (2019)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
por: Haist, Maximilian, et al.
Publicado: (2023)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
por: Sa, Ho-Seok, et al.
Publicado: (2022)

Safety of sequential immune checkpoint inhibitors after prior immune therapy
por: Awidi, Muhammad, et al.
Publicado: (2022)

Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis
por: Suay, Guillermo, et al.
Publicado: (2023)

Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma
por: Angell, Trevor E., et al.
Publicado: (2017)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis
por: Li, Ping, et al.
Publicado: (2018)

Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients
por: Pescarmona, Rémi, et al.
Publicado: (2021)

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
por: Li, Liu, et al.
Publicado: (2023)

Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy
por: Pohl, Julia, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Therapy: A Boon to Elderly Patients with Advanced Melanoma?
por: Muta, Tsuyoshi
Publicado: (2018)

Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma
por: Wu, Minliang, et al.
Publicado: (2019)

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2022)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Jiang, Ben‐Yuan, et al.
Publicado: (2021)

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
por: González-Navajas, Jose M., et al.
Publicado: (2021)

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
por: Lai, Xiulan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qkv7q0c36acug28l2n19kqeo7k